TCM Biotech International (ROCO:4169) 3-Year EBITDA Growth Rate : -5.80% (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is TCM Biotech International 3-Year EBITDA Growth Rate?

TCM Biotech International's EBITDA per Share for the six months ended in Dec. 2023 was NT$0.45.

During the past 12 months, TCM Biotech International's average EBITDA Per Share Growth Rate was -5.10% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -5.80% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 0.60% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 6.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of TCM Biotech International was 37.00% per year. The lowest was -21.50% per year. And the median was 13.60% per year.

Competitive Comparison of TCM Biotech International's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, TCM Biotech International's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TCM Biotech International's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TCM Biotech International's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where TCM Biotech International's 3-Year EBITDA Growth Rate falls into.

TCM Biotech International 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

TCM Biotech International (ROCO:4169) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

TCM Biotech International 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of TCM Biotech International's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

TCM Biotech International (ROCO:4169) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TCM Biotech International Corp (ROCO:4169) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 97, Sec. 1, Xintai 5th Road, Xizhi District, Neihu District, Taipei, TWN, 221

Website

http://www.tcmbio.com

TCM Biotech International Corp is a Taiwan based biotechnology company. It is engaged in the research and development of therapeutics for the prevention and treatment of liver diseases. Its products includes Anti-adhesion System, Anti-neoplastic agents, Osteoporosis Treatment Preparation, Iron Preparations, Osteoarthritis (OA) Treatment Products, Urinary System Treatment Products and others. The company has a business presence in Taiwan and other international countries such as the United States, Japan, Singapore, Malaysia, Vietnam, the Philippines and China. The entity derives key revenue from the sales of multiple medical products which includes medicine, medical device, functional food and others.

TCM Biotech International (ROCO:4169) Headlines

No Headlines